New combo therapy aims to boost growth in kids with dwarfism
NCT ID NCT06433557
First seen Feb 19, 2026 · Last updated May 20, 2026 · Updated 12 times
Summary
This study tests whether two weekly injections, navepegritide and lonapegsomatropin, can safely improve growth in children aged 2 to 11 with achondroplasia (a common form of dwarfism). The trial involves 22 children and lasts 156 weeks. The goal is to see if the combination works better than either drug alone, but ongoing treatment is needed, so it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascendis Pharma Investigational Site
Copenhagen, 2100, Denmark
-
Ascendis Pharma Investigational Site
Dublin, D01 YC76, Ireland
-
Ascendis Pharma Investigational Site
London, W1W 5AH, United Kingdom
Conditions
Explore the condition pages connected to this study.